SciClone Pharmaceuticals (NASDAQ:SCLN) managed to stay afloat and traded higher with an addition of 0.73 point or 5.36% at $14.36. The money flow data is a negative $(-1.25) million with $1.92 million in upticks and $3.18 million in downticks. The intraday up/down ratio came in at 0.6. The shares have seen 2.79% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $0.18 million and the combined worth of the downticks was $1.2, Million, leading to the up/down ratio of 0.15. The block trade saw a net money flow of $(-1.02) million.
Currently the company Insiders own 6.95% of SciClone Pharmaceuticals shares according to the proxy statements. Institutional Investors own 79.03% of SciClone Pharmaceuticals shares. On the companys insider trading activities, Blobel Friedhelm, director officer (President & CEO) of Sciclone Pharmaceuticals Inc, unloaded 10,000 shares at an average price of $9.29 on March 28, 2016. The total amount of the transaction was worth $92,900, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
SciClone Pharmaceuticals (NASDAQ:SCLN) : On Monday heightened volatility was witnessed in SciClone Pharmaceuticals (NASDAQ:SCLN) which led to swings in the share price. The stock opened for trading at $13.54 and hit $14.63 on the upside , eventually ending the session at $14.36, with a gain of 5.36% or 0.73 points. The heightened volatility saw the trading volume jump to 1,031,651 shares. The 52-week high of the share price is $14.63 and the company has a market cap of $717 million. The 52-week low of the share price is at $6.47 .
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Companys lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.